Guardian Pharmacy Services, Inc. (GRDN) Earnings
Guardian Pharmacy Services, Inc. is expected to report next earnings on August 10, 2026 (in NaN days), with a consensus EPS estimate of $0.26. GRDN has beaten EPS estimates in 3 of its last 3 reported quarters (average surprise +24.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.24 | $0.29 | +20.8% | $337M | +2.0% |
| Mar 11, 2026 | $0.27 | $0.37 | +38.3% | $398M | +18.5% |
| Mar 26, 2025 | $0.21 | $0.24 | +14.3% | $339M | +4.8% |
| Sep 26, 2024 | — | $0.17 | — | $300M | — |
| Dec 31, 2023 | — | $0.10 | — | $1.0B | — |
| Sep 30, 2023 | — | $-0.19 | — | $263M | — |
| Jun 30, 2023 | — | $0.35 | — | $253M | — |
| Jun 30, 2022 | — | $-0.10 | — | $224M | — |
| Mar 31, 2022 | — | $0.30 | — | $211M | — |
| Dec 31, 2021 | — | $0.07 | — | $792M | — |
| Sep 30, 2021 | — | $0.20 | — | $204M | — |
| Sep 30, 2020 | — | $-0.05 | — | $182M | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Fred Burke mentioned that Guardian delivered solid results in the first quarter, with a 2% revenue increase despite a 60% decline in pricing across branded drug mix impacted by IRA. They proactively took actions to offset IRA's approximately $10 million headwind, achieving double-digit gross profit growth. The IRA introduced changes in operational mechanics, payment timing, and cash flow, but the team navigated them effectively. Also, the IRA created a one-time working capital reset, which Guardian managed. David Morris discussed underlying drivers like total residents up 10%, script volumes up 10%, revenue from organic growth, acquisitions, and plan optimization. SG&A included $3.2 million legal expense related to reimbursement, and a $8.5 million cash payment will be recognized in Q2. Acquisitions' profitability dampened margins by 80 basis points. Balance sheet had $65 million cash, flat with year end. Revenue guidance remains $1.4 to $1.42 billion, adjusted EBITDA guidance updated to $123 million to $127 million.
Guidance
Revenue guidance remains at $1.4 to $1.42 billion. Adjusted EBITDA guidance updated to $123 million to $127 million, up from $120 million to $124 million, reflecting $3 million discrete benefits recognized in the quarter. Capital allocation priorities remain with acquisitions and greenfield investments. Confident in underlying growth drivers and IRA impact visibility.
Segment performance
Revenue for the quarter was $336.6 million, up 2% year over year. Gross profit was $76 million, up 19% year over year. Total residents increased 10% year over year to approximately 207,000 at the quarter end, with assisted living residents representing roughly 70% of the mix. Script volumes were also strong, increasing 10% year over year. Absent the government mandated price declines from the IRA, revenues would have been up low double digits year over year. Gross profit, absent the $3 million benefit, grew 14%. Acquisitions completed over the past two years are collectively contributing modest profitability in the quarter, but remaining well below the consolidated margin profile, dampening margins by approximately 80 basis points.
Risks & headwinds
Potential continued volatility in fuel prices, which could be a headwind of up to a few million dollars annually if prices remain elevated. Labor costs likely to trend modestly higher over remainder of year due to scaling and organizational infrastructure investment. Uncertainty around near-term legislative relief for IRA's unintended consequences.